Members
| Location: | Laval, Quebec |
|---|---|
| Industry Sector: | Pharma |
| Website: | www.sanofi-aventis.ca |
| Contact: |
Carolin Martel (caroline.martel@sanofi.com) 1 514 331 9220 |
| Ownership: | Subsidiary - : |
| Description: | Sanofi S.A. is a French multinational pharmaceutical company headquartered in Paris, France. Sanofi engages in the research and development, manufacturing and marketing of pharmaceutical products for sale principally in the prescription market, but also develops over-the-counter medication. The company covers 7 major therapeutic areas: cardiovascular, central nervous system, diabetes, internal medicine, oncology, thrombosis and vaccines. Sanofi Canada Inc. is the Canadian affiliate of the sanofi- Group. The Company is active in developing, innovative medicines for treatments in several therapeutic areas: cardiovascular disease, thrombosis, oncology, metabolic disorders, the central nervous system, and internal medicine. |
| Location: | Toronto, Ontario |
|---|---|
| Industry Sector: | Pharma |
| Website: | www.sanofipasteur.ca |
| Contact: |
Nancy Simpson (nancy.simpson@sanofipasteur.com) 1 416 6672701 |
| Ownership: | Subsidiary - : |
| Description: | Sanofi Pasteur, is the vaccines division of Sanofi Group. Sanofi Pasteur's mission is to protect and improve human health worldwide by providing superior, innovative vaccines for the prevention and treatment of disease, playing an active role in the immunization community. Sanofi Pasteur offers the broadest range of vaccines, protecting against 20 infectious diseases. The site at Toronto, includes Canada's largest R&D facilities for vaccines, in addition to manufacturing and distribution operations. |
| Location: | Sarnia, Ontario |
|---|---|
| Industry Sector: | Public / Non-Profit Organizations |
| Website: | www.sarnialambton.on.ca |
| Contact: |
George Mallay (mallay@sarnialambton.on.ca) 1 519 332 1820 |
| Description: | Sarnia-Lambton is an engineering, research, development and product-commercialization centre for the petrochemical and refining industries. |
| Location: | Saskatoon, Saskatchewan |
|---|---|
| Industry Sector: | Public / Non-Profit Organizations |
| Website: | www.src.sk.ca |
| Contact: |
Laurier L. Schramm (humanresources@src.sk.ca) 1 306 933 5400 |
| Description: | SRC is Saskatchewan's leading provider of applied R&D and technology commercialization. SRC is a market driven company,selling services in Saskatchewan and around the world. |
| Location: | London, Ontario |
|---|---|
| Industry Sector: | Medical Technology |
| Website: | www.sernovacorp.com |
| Contact: |
Philip M. Toleikis (philip@sernova.com) 1 519 858 5184 |
| Ownership: | Public - Toronto Stock Exchange (TSX): SVA.V |
| Description: | Sernova Corp. is a Canadian-based Clinical Stage MedTech company committed to developing and commercializing products which benefit patients with chronic metabolic, neurological, and haematological diseases first product with a first product focus on diabetes. Sernova has two platform technologies. The first is the Cell Pouch System(TM) an implantable medical device for the long-term survival and function of therapeutic cells. The second is Sertolin(TM) a cell based technology which provides local immune protection to therapeutic cells enabling the potential elimination of antirejection drugs. Sernova is initiating clinical trials of its Cell Pouch(TM) to treat insulin-dependent diabetes based on it very compelling preclinical results in isograft, autograft and allograft cell transplantation models of diabetes. |
| Location: | Toronto, Ontario |
|---|---|
| Industry Sector: | Biotechnology - Therapeutics and Diagnostics |
| Website: | www.shirecanada.com |
| Contact: |
Cherise Kent (info@shirecanada.com) 1 416 2256100 |
| Ownership: | Subsidiary - London Stock Exchange (LSE): SHP |
| Description: | Shire Human Genetic Therapies (Canada)") is a wholly owned subsidiary of Shire plc, a global specialty biopharmaceutical company that works closely with specialist physicians to develop and market medicines that improve the quality of life for patients, their families and caregivers. Shire Human Genetic Therapies (Canada) develops treatments for genetic disorders known as rare or orphan diseases. |
| Location: | Richmond, British Columbia |
|---|---|
| Industry Sector: | Biotechnology / R&D Services |
| Website: | www.signalchem.com |
| Contact: |
(info@signalchem.com) 1 604 232 4600 |
| Description: | SignalChem is a biotechnology company providing human recombinant proteins for studying cell signaling. They produce highly active kinases, phosphatases, phosphodiesterases, histone deacetylases, sirtuins, and other cellular proteins involved in signal transduction. |
| Location: | Edmonton, Alberta |
|---|---|
| Industry Sector: | Pharma |
| Website: | www.sinoveda.com |
| Contact: |
Yun K. Tam (knowledge@sinoveda.com) 1 780 4660086 |
| Description: | SinoVeda Canada Inc. is a private company founded by two pharmaceutical scientists in 2006. The company is built on the understanding that a disease is a complicated process that can only be treated with products that take aim at multiple therapeutic targets. The vision of the Company is to make highly safe and efficacious pharmaceuticals from active botanicals by using pharmaceutical technology to develop drugs derived from botanical medicines using a multiple ingredient and multiple target approach. SinoVeda’s patent pending technology, PPT®, is an in vitro and in silico physiological PK/PD model which is used for screening active moieties in a complex mixture, similar to that of a medicinal herb. This technology is proven and operational; it has been used successfully to develop a pipeline of products, which are going into clinical trials in 2012/2013 and are anticipated be launched in the global market by 2013. The pharmaceutical industry is actively seeking for a new paradigm to enrich its rapidly dwindling pipeline of new products. Using current approaches to R & D, industry experience is that 5 out of 10,000 compounds make it to the clinical phase and only one out of these 5 candidates will make it to the market. SinoVeda’s strategy and patent pending technology improves these odds significantly. The Company focuses on botanicals with proven therapeutic results and utilizes its technology to identify and standardize pharmaceutical grade combinations of the specific bio active ingredients within those botanicals that generate these results. These combinations can then be made into pharmaceuticals synthetically. While the core structures of over 60% of pharmaceuticals are derived from botanicals, there is a fundamental flaw in current drug development strategies from botanicals which stems from the failure to recognize that a disease condition is usually associated with multiple conditions and thus requires multiple compounds for proper treatment. At SinoVeda,PPT (R) allows us to identify the active ingredients of clinically effective botanicals and improves our understanding of the mechanisms of action of these ingredients, thus eliminating the current shortcomings of botanical medicines. |
| Location: | Vancouver, British Columbia |
|---|---|
| Industry Sector: | Biotechnology / R&D Services |
| Website: | www.siriusgenomics.com |
| Contact: |
Chris Wagner (cwagner@siriusgenomics.com) 1 604 4847195 |
| Description: | Sirius Genomics is a private biotechnology company, based in Vancouver, British Columbia that develops companion diagnostics (CDx) for acute medical conditions. Sirius' focus is on developing companion diagnostics for therapeutics leading to better patient outcomes through personalized medicine. Currently, therapeutics follow a one-size-fits-all pattern. However, the inherent genetic differences between individuals can lead to low efficacy or adverse side effects for a drug, thereby limiting its clinical utility. Sirius addresses this problem by developing companion diagnostics which identify patient populations that will benefit the most from pharmaceutical therapeutics. This will enable patients to get the right medication, doctors to more effectively treat the critically ill, and drug companies to fully realize the market potential for their therapeutics. By correlating patient genetics and other markers with clinical outcomes, Sirius’ CDx products aim to enable more effective drug treatment. |
| Location: | Vancouver, British Columbia |
|---|---|
| Industry Sector: | Biotechnology - Therapeutics and Diagnostics |
| Website: | www.sironabiochem.com |
| Contact: |
Julie Jang (jjang@sironabiochem.com) 1 604 6414466 |
| Ownership: | Public - Toronto Stock Exchange (TSX): SBM.V |
| Description: | Sirona Biochem Corp. is a biotechnology company developing three major programs in diabetes and obesity therapeutics, anti-aging cosmeceuticals, and biological ingredients. Sirona Biochem specializes in the development of carbohydrate-based molecules. The company's most advanced program, a sodium glucose co-transporter (SGLT) for diabetes, achieved positive preclinical results. |
| Location: | Ottawa, Ontario |
|---|---|
| Industry Sector: | Professional Services and Consulting |
| Website: | www.smart-biggar.ca |
| Contact: |
David E. Schwartz (ottawa@smart-biggar.ca) 1 613 232 2486 |
| Description: | Smart & Biggar/Fetherstonhaugh is Canada's largest firm practicing exclusively in intellectual property and technology law, with offices in Ottawa, Toronto, Montreal and Vancouver. They have been committed to providing the highest quality service for over a hundred years and are proud that numerous independent surveys consistently place them at the top of their rankings in Canadian IP Law. |
| Location: | Fredericton, New Brunswick |
|---|---|
| Industry Sector: | Biotechnology - other |
| Website: | www.solanumgenomics.ca |
| Contact: |
John Argall (jargall@bioatlantech.nb.ca) 1 506 444 2444 |
| Description: | Solanum Genomics is involved in potato research and development. |
| Location: | Milford, Connecticut |
|---|---|
| Industry Sector: | Professional Services and Consulting |
| Website: | www.somersetcapital.com/ |
| Contact: |
(info@somersetcapital.com) 1 877 282 9922 |
| Description: | Headquartered in Milford, CT, Somerset Capital was established in 1984 and offers equipment leasing, rental and asset management solutions, with a strong focus and capability in life sciences technology including microscopy, protein separation, mass spectrometry, cellular analytcal systems, centrifugation, packaging/fillers and other assets. Somerset Capital's clients include major corporations, pharma, biotech research, not-for-profits and household academic entities and their research departments. Somerset Capital’s primary operations are in the US with additional operations in Canada, Singapore, Taiwan and the UK. |
| Location: | Toronto, Ontario |
|---|---|
| Industry Sector: | Professional Services and Consulting |
| Website: | www.soundinsurance.ca |
| Contact: |
Neil Mahajan (neilm72@hotmail.com) 1 416 646-0199 |
| Description: | Sound Insurance Services Inc. is a privately owned and operated Canadian Independent Insurance Brokerage providing insurance products and services. |
| Location: | Winnipeg, Manitoba |
|---|---|
| Industry Sector: | Supplier & Engineering |
| Website: | www.sphaeragroup.com |
| Contact: |
(info@sphaeragroup.com) 1 204 6335003 |
| Description: | Sphaera Technologies Inc. is a leading engineering firm that provides a diverse set of services. Their Biomedical Division specializes in complete medical device development solutions. |
| Location: | Toronto, Ontario |
|---|---|
| Industry Sector: | Biotechnology - Therapeutics and Diagnostics |
| Website: | www.stemcellthera.com |
| Contact: |
David Allan (dallan@stemcellthera.com) 1 647 258.4325 |
| Ownership: | Public - Toronto Stock Exchange (TSX): SSS.V |
| Description: | Stem Cell Therapeutics Corp. is a biotechnology company focused on the development and commercialization of drug-based therapies to treat central nervous system (“CNS”) disorders. The Company's programs aim to repair brain and nerve function lost due to disease or injury. |
| Location: | Caledon, Ontario |
|---|---|
| Industry Sector: | Biotechnology - Therapeutics and Diagnostics |
| Website: | www.stxbpharma.com/?view=featured |
| Contact: |
(info@stxbpharma.com) 1 416 894.4317 |
| Description: | STxB™ Pharma Technologies Inc. is a clinical-stage company, developing cell targeting technologies with a particular focus in cancer and infectious diseases. The company is leveraging the vectoring capabilities of its ShigaTek™ technology to create both therapeutic vaccines (with a primary focus on cancer) and targeted anti-cancer agents vectored directly to tumour cells. Based on the ShigaTek™ platform technology, the company is developing a pipeline of products for both immunotherapy and tumour targeting applications, including a companion diagnostic. STxB™ is collaborating with the expert scientific teams headed by Dr. Ludger Johannes at the Institut Curie and Dr. Eric Tartour at the Hopital European Georges Pompidou and will start Canadian-based Research & Development activities in 2013. |
| Location: | Vancouver, British Columbia |
|---|---|
| Industry Sector: | Pharma |
| Website: | www.supernapharma.com |
| Contact: |
Bruce Clarke (info@supernapharma.com) 1 877 469 1254 |
| Description: | Superna Life Sciences is a specialty pharmaceutical company focused on the commercialization of treatments for niche diseases and indications, primarily hematology and oncology, in the Canadian marketplace. |
| Location: | Fredericton, New Brunswick |
|---|---|
| Industry Sector: | Biotechnology - other |
| Website: | www.sylvar.ca |
| Contact: |
John Argall (info@sylvar.ca) 1 506 444 5690 |
| Description: | Sylvar Technologies Inc. develops and offers safe and environmentally-friendly biopesticide technology solutions for controlling forest pests. |
